Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-59020

ABSTRACT: ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells (RNA-Seq)

OTHER RELATED OMICS DATASETS IN: PRJNA254144PRJNA254145

PROVIDER: E-GEOD-59020 | ExpressionAtlas | 2025-01-24

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-59020-analysis-methods.tsv	Tabular
	E-GEOD-59020-analytics.tsv	Tabular
	E-GEOD-59020-analytics.tsv.undecorated	Tabular
	E-GEOD-59020-analytics.tsv.undecorated.unrounded	Tabular
	E-GEOD-59020-analytics.tsv.unrounded	Tabular

Items per page:

1 - 5 of 51

Similar Datasets

Homo sapiens

Project description:ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells (RNA-Seq)

| PRJNA254145 | ENA

Homo sapiens

Project description:ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells (ChIP-Seq)

| PRJNA254144 | ENA

ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells

Project description:ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells

| PRJNA254143 | ENA

Transcription profiling of C. elegans with activated let-60 Ras

Project description:In Caenorhabditis elegans, let-60 Ras controls many cellular processes, such as differentiation of vulval epithelial cells, function of chemosensory neurons, and meiotic progression in the germ line. Although much is known about the let-60 Ras signaling pathway, relatively little is understood about the target genes induced by let-60 Ras signaling that carry out terminal effector functions leading to morphological change. We have used DNA microarrays to identify 708 genes that change expression in response to activated let-60 Ras.

2005-07-13 | E-SMDB-1398 | biostudies-arrayexpress

Downstream targets of let-60 Ras in Caenorhabditis elegans

2005-07-22 | E-GEOD-2974 | biostudies-arrayexpress

Characterization of RAS and SLC3A2 signaling in multiple myeloma

Project description:Oncogenic mutations within the RAS pathway are common in multiple myeloma (MM), an incurable malignancy of plasma cells. However, the mechanisms of pathogenic RAS signaling in this disease remain enigmatic and difficult to inhibit therapeutically. We employed an unbiased proteogenomic approach to dissect RAS signaling in MM by combining genome-wide CRISPR-Cas9 screening with quantitative mass spectrometry focused on RAS biology. We discovered that mutant isoforms of RAS organized a signaling complex with the amino acid transporter, SLC3A2, and MTOR on endolysosomes, which directly activated mTORC1 by co-opting amino acid sensing pathways. MM tumors with high expression of mTORC1-dependent genes were more aggressive and enriched in RAS mutations, and we detected interactions between RAS and MTOR in MM patient tumors harboring mutant RAS isoforms. Inhibition of RAS-dependent mTORC1 activity synergized with MEK and ERK inhibitors to quench pathogenic RAS signaling in MM cells. This study redefines the RAS pathway in MM and provides a mechanistic and rational basis to target this novel mode of RAS signaling.

2022-10-14 | PXD031662 | Pride

Downstream targets of let-60 Ras in Caenorhabditis elegans

2005-07-22 | GSE2974 | GEO

UPenn CAR T cell Responders and Non-responders

Project description:<p>The adoptive transfer of autologous T cells genetically modified to express a CD19-specific, 4-1BB/CD3zeta-signaling chimeric antigen receptor (CAR; CTL019) has shown remarkable activity in patients with B acute lymphoblastic leukemia. Similar therapy can induce long-term remissions for relapsed/refractory chronic lymphocytic leukemia (CLL) patients, but in only a small subset of subjects. The determinants of response and resistance to CTL019 therapy of CLL are not fully understood. We employed next generation sequencing of RNA (RNA-seq) to identify predictive indicators of response to CTL019 treatment. We performed RNA-seq on leukapheresis and manufactured infusion product T cells from patients with heavily pre-treated and high-risk disease. To characterize potency, we also performed RNA-seq on the cellular infusion product after CAR-specific stimulation. Our findings indicate that durable remission in CLL is associated with gene expression signatures of early memory T cell differentiation (e.g., STAT3), while T cells from poorly- or non-responding patients exhibited elevated expression of key regulators of late memory as well as effector T cell differentiation, apoptosis, aerobic glycolysis, hypoxia and exhaustion. These gene expression signatures, along with additional immunological biomarkers, may be used to identify which patients are most likely to respond to cellular therapies and suggest manufacturing modifications that might potentiate the generation of maximally efficacious infusion products.</p>

| phs001707 | dbGaP

RNA-Seq of Ras induced Epithelial to Mesenchymal Transition (EMT) in Madin-Darby Canine Kidney (MDCK) cells

Project description:To gain more information about EMT induced by oncogenic Ras in MDCK cells, we performed RNA-seq of MDCK and MDCK-Ras cells and compared their genome-wide gene expression profiles.

2016-02-03 | E-MTAB-3301 | biostudies-arrayexpress

Etv4 and Etv5 binding sites in EpRas mouse mammary gland epithelial cell line [ChIP-seq]

Project description:We searched for roles of Etv4 and Etv5 during EMT through genome-wide analysis of their binding sites in Ras-transformed mammary gland epithelial cells.

2017-04-10 | GSE89618 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data